GX 188E

Drug Profile

GX 188E

Alternative Names: GX-188; GX188E; pGX27-E6E7

Latest Information Update: 23 Nov 2016

Price : $50

At a glance

  • Originator Genexine
  • Class Cancer vaccines; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Cervical intraepithelial neoplasia
  • Preclinical Human papillomavirus infections

Most Recent Events

  • 16 Nov 2016 Genexine and Merck and Co agree to co-develop GX 188E in combination with pembrolizumab for Cancer (HPV induced)
  • 16 Nov 2016 Genexine and Merck and Co. plan a phase Ib/IIa trial for Cancer (HPV induced) (Combination therapy)
  • 14 Jan 2016 Preclinical trials in Human papillomavirus infections in South Korea (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top